Express Scripts (ESRX) Reports Conclusion of Probe on Disposition of PolyMedica
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Oppenheimer Remains Sidelined on Express Scripts (ESRX) Following 3Q
November 1, 2016 10:00 AM EDTOppenheimer reiterated a Perform rating on Express Scripts (NASDAQ: ESRX) following the company's 3Q. ESRX reported 3Q revenues of $25.4B vs. consensus of $25.5B. Adjusted EPS was $1.74 vs. consensus of $1.73 and $1.72-1.76 guidance. 4Q Adjusted EPS was guided to $1.84-1.90 vs. consensus' $1.85 estimate.... More
